Section Arrow
Quote
STOK.NASDAQ
- Stoke Therapeutics
Quotes are at least 15-min delayed:2025/06/12 09:10 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
11.5 
1-M High
11.81 
Volume 
-- 
Bid
10.8
Ask
11.7
Day Low
-- 
Open
-- 
1-M Low
8.7032 
Market Cap 
627.86M 
Currency USD 
P/E 14.02 
%Yield -- 
10-SMA 10.7 
20-SMA 10.11 
50-SMA 8.98 
52-W High 16.62 
52-W Low 5.35 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.82/-3.12
Enterprise Value
627.86M
Balance Sheet
Book Value Per Share
6.41
Cash Flow
Cash Flow Yield
0.11
Income Statement
Total Revenue
36.56M
Operating Revenue Per Share
0.17
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%0PE
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%5.54PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2025/06/12 09:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.